文献速递骨质疏松与钙磷/甲状旁腺

Jansen病:软骨发育不良之外的骨骼异常

Jansen's Disease: Bone Abnormalities Beyond Chondrodysplasia.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

本研究对2例携带H223R-PTH1R突变的Jansen干骺端软骨发育不良(JMC)患儿及9名健康对照的髂骨活检样本进行骨组织形态计量、免疫组化和组织学分析,发现患者骨结构不规则、类骨质增多、矿化延迟、骨细胞形态异常及骨细胞来源蛋白表达改变。

要点

  • JMC患者骨小梁体积正常,但骨结构不规则、类骨质增多且成熟延迟。
  • 患者骨细胞陷窝和小管内类骨质堆积,骨细胞网络异常。
  • 患者骨细胞FGF23染色增强而硬化蛋白染色减弱。

核心结论

  • JMC患者的H223R-PTH1R突变导致骨结构不规则、矿化不足、骨细胞形态异常及骨细胞来源蛋白表达改变。
  • 这些发现强调突变PTH1R对骨生理的多方面影响,并将骨细胞作为治疗干预的细胞靶点。
  • 骨细胞基因表达正常化是否可能并改善JMC患者骨骼健康尚待观察。
  • 评估骨细胞形态和功能可能为未来JMC治疗临床试验提供新的诊断终点。

研究设计与样本

  • 对2例携带H223R-PTHR1突变的JMC男性同胞(年龄6岁和8岁)及9名年龄相近、肾功能正常的健康对照男性的髂骨活检样本进行骨组织形态计量、免疫组化和组织学分析。

主要发现

  • 2例JMC患者均显示骨结构不规则、类骨质增多和类骨质成熟过程延长。
  • 骨小梁体积保持正常,但免疫组化分析显示骨表面成骨细胞和成纤维细胞中PTH1R表达增加。
  • 皮质骨显示强烈破骨细胞活性的区域和散在的骨髓纤维化。
  • JMC患者样本中的骨细胞陷窝和小管内类骨质堆积,且小管更短、更少。
  • DMP1免疫组化突显患者小管网络异常;骨细胞中FGF23染色增强而硬化蛋白染色减弱。

局限性

  • 骨细胞基因表达正常化是否可能并改善JMC患者骨骼健康尚待观察。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Jansen metaphyseal chondrodysplasia (JMC) is an ultra-rare autosomal dominant disease that is caused by heterozygous, activating PTH1R mutations resulting in PTH- and PTHrP-independent hypercalcemia and hypercalciuria, leading to nephrocalcinosis and impaired renal function later in life. The activated PTH1R plays critical roles in mineral ion homeostasis and bone lengthening, as well as bone formation and resorption. Currently, little is known about bone turnover markers and bone histomorphometric changes in JMC patients. OBJECTIVE: This study aimed to assess changes in bone microarchitecture, bone formation, and bone protein expression in 2 pediatric patients with JMC harboring the H223R-PTHR1 mutation. METHODS: Bone histomorphometry, immunohistochemistry, and histologic analyses were conducted on iliac crest biopsy samples from 2 male siblings affected by JMC (ages 6 and 8 years) and 9 healthy control males of similar age, with normal kidney function. RESULTS: Both patients with JMC displayed irregular bone architecture, increased osteoid, and a prolonged osteoid maturation process. While trabecular volume remained normal, immunohistochemical analysis demonstrated increased in PTH1R expression in both osteoblasts and fibroblastic cells on the bone surface. Cortical bone displayed areas of intense osteoclast activity and scattered marrow fibrosis. Remarkably, osteocytes in samples from patients with JMC had osteoid buildup within their lacunae and canaliculi that were both shorter and less abundant. DMP1 immunohistochemistry highlighted the abnormal canalicular network in patients. FGF23 staining in osteocytes was enhanced while sclerostin was diminished. CONCLUSION: The H223R-PTH1R mutation in patients with JMC leads to bone structural irregularities, hypomineralization, abnormal osteocyte morphology, and altered expression of osteocyte-derived proteins. These findings underscore the multifaceted impact of the mutant PTH1R on bone physiology and focus attention on the osteocyte as a cellular target for therapeutic intervention. Whether normalizing gene expression in osteocytes is possible and can improve bone health in patients with JMC remains to be seen. Assessment of osteocyte morphology and function may provide novel diagnostic endpoints for future clinical trials with JMC therapeutics.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Pereira RC, Delany AM, Reyes M, et al. Jansen's Disease: Bone Abnormalities Beyond Chondrodysplasia. J Clin Endocrinol Metab. 2025. PMID: 39950977. doi:10.1210/clinem/dgaf097

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。